David Nierengarten: Stocks like Y-mAbs Therapeutics Which Have Advanced Assets as Well as Upside Potential
David Nierengarten: Y-mAbs Therapeutics Should be Particularly Attractive for Investors.
Robert Driscoll: Cidara's Partnership with Mundipharma is a Significant Positive
Robert Driscoll: We See Substantial Synergies Between Both Cidara and Mundipharma Given Mundipharma Already has a Significant Global Commercial Reach with Annual Sales Over €2B
Technology Sector Investors in a Defensive Mode
Michael Pachter: Few Near-Term Catalysts Ahead of the Nov. 15 Launch of EA’s Star Wars Jedi: Fallen Order
Upcoming iPhone Models Could Boost Apple Stock Regardless of Trade Tariffs
Michael Pachter: They are Hopeful That A Lot of People in the Chain of Decision-Making is Thinking About Life After the DOD and Life In the Private Sector.
Daniel Ives: There Has Been an Accelerations of Large Enterprise Cloud Deals During the Second Quarter in the U.S. and Europe and That Microsoft is Poised to Win Many of Them
Michael Pachter: Few Near-term Catalysts Ahead of Nov. 15 Launch of "Star Wars Jedi: Fallen Order